DOCSLIB.ORG

View PDF Version

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
View PDF Version RSC Advances View Article Online REVIEW View Journal | View Issue A comprehensive overview of vaccines developed for pandemic viral pathogens over the past two Cite this: RSC Adv.,2021,11, 20006 decades including those in clinical trials for the current novel SARS-CoV-2 Kannan Damodharan, ab Gandarvakottai Senthilkumar Arumugam,b Suresh Ganesan,b Mukesh Doble *b and Sathiah Thennarasua The unprecedented coronavirus disease 2019 (COVID-19) is triggered by a novel strain of coronavirus namely, Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2). Researchers are working around the clock to control this pandemic and consequent waves of viral reproduction, through repurposing existing drugs as well as designing new vaccines. Several countries have hastened vaccine design and clinical trials to quickly address this outbreak. Currently, more than 250 aspirants against SARS-CoV-2 are in progress, including mRNA- replicating or non-replicating viral vectored-, DNA-, autologous dendritic cell-based-, and inactivated virus- Creative Commons Attribution-NonCommercial 3.0 Unported Licence. vaccines. Vaccines work by prompting effector mechanisms such as cells/molecules, which target quickly replicating pathogens and neutralize their toxic constituents. Vaccine-stimulated immune effectors include adjuvant, affinity, avidity, affinity maturation, antibodies, antigen-presenting cells, B lymphocytes, carrier protein, Received 13th November 2020 CD4+ T-helper cells. In this review, we describe updated information on the various vaccines available over the Accepted 14th January 2021 last two decades, along with recent progress in the ongoing battle developing 63 diverse vaccines against SARS- DOI: 10.1039/d0ra09668g CoV-2. The inspiration of our effort is to convey the current investigation focus on registered clinical trials (as of rsc.li/rsc-advances January 08, 2021) that satisfy the safety and efficacy criteria of international wide vaccine development. This article is licensed under a aDepartment of Organic and Bioorganic Chemistry, CSIR-Central Leather Research bBioengineering and Drug Design Lab, Department of Biotechnology, Indian Institute Institute (CLRI), Chennai, 600020, India of Technology Madras (IITM), Chennai, 600032, India. E-mail: mukesh.doble0@ gmail.com; [email protected] Open Access Article. Published on 08 June 2021. Downloaded 9/28/2021 7:21:02 PM. Kannan completed his B.Sc. Senthilkumar obtained chemistry degree at A. V. C. his M.Sc. chemistry at Bhar- College, Mayiladuthurai, affili- athidasan University, where he ated to Bharathidasan Univer- was involved in mechanistic sity, and M.Sc. in chemical studies of anticancer drugs. He sciences at Pondicherry Univer- then explored new drug sity, India. He obtained his PhD discovery and development from (organic chemistry) at the marine and medicinal plants, University of Madras, India. and their synthesis which is been Later, he took a research asso- developed at IIT Madras, IISc ciate position at the Department Bangalore and IIT Kanpur. He of Biotechnology, IIT Madras, developed variegated drug then moved to Taiwan for candidates at IIT Madras, such research at Tamkang University, Taiwan. Then he was employed as phosphate binder resin, sevcar (two patents); and tolvaptan, as a SERB-post-doctoral fellow at the CSIR-Central Leather hyponatremia and cystagon; and drugs from Terminalia arjuna. Research Institute, Chennai, India. He has synthesized substituted He then engaged in the peptidomimetic domain for antitumor alkynylated hybrid molecules and utilized them for NIR and EL screening at IISc Bangalore. Then back at IIT Madras worked on applications; and liquid crystalline-, steroidal-based materials for transitmycin, which is in phase-II pre-clinical trials. He has also sensor and biomedical applications; he also worked on the char- discovered new blood, breast, and liver cancer drugs, and diabetic acterization of natural product transitmycin. treatments. Recently, he also discovered, arjunetin, that is a better candidate for COVID-19 treatment than FDA approved drugs. 20006 | RSC Adv.,2021,11, 20006–20035 © 2021 The Author(s). Published by the Royal Society of Chemistry View Article Online Review RSC Advances Introduction Chemically, adjuvants are a highly heterogeneous group of compounds (including Al salts). One of the most successful therapeutic strategies to prevent or Antibiotics. Used in lower amounts during the develop- control various diseases is by “vaccination” protocol.1,2 Millions ment phase, to circumvent bacterial infection during tissue of lives have been saved because of vaccinations, which cover culture cells where the viruses are grown. MMR (measles, a number of diseases including certain types of cancer, HIV and mumps, rubella) and IPV (inactivated polio vaccine) associ- many viral infections.3 Vaccination was initially accomplished ated vaccines have a minimum amount (<25 mg) of neomycin by Edward Jenner, who was the pioneer for smallpox in the late for each dose. 18th century.4 In the 1980s, the development of vaccines to ght The MMR vaccine was developed by Maurice Hilleman in against pathogenic microorganisms was tentatively introduced. 1971. Mumps, like measles infections, are caused by an RNA Vaccines are now employed to improve and increase the based virus from the Paramyxoviridae family. Moreover, protection capability (immunity) of the body to ght severe measles and mumps belong to the genus Rubulavirus, it is infection and disease,5 and moreover, primarily intend to make a human disease with no animal reservoirs. Generally, the MMR ff immunity stronger and reduce resistivity of diseases by vaccine exhibits side e ects of a painful arm from the shot, reducing the reproduction of target pathogens. The majority of minor rashes, generally in teen/adult women who have no vaccines actively exist in the immune system, since anti-bodies earlier immunity; then the rubella vaccine component can ff are constantly generated in the body to sustain a healthy result in joint and tendon sti ness. This vaccine is also asso- immunity system.6,7 ciated with the minor threat of seizures/jerking instigated by fever, but is not connected with any enduring effects. The threat of febrile seizures increases as infants get older, hence this General components of vaccines vaccine is recommended at a young age. Some people may A vaccine consists of an antigen, stabilizer, adjuvant, antibiotic, experience cheek/neck inammation, impermanent low 8 Creative Commons Attribution-NonCommercial 3.0 Unported Licence. preservative, and chemical reagents such as formaldehyde. The platelet counts that generally do not require treatment and are advantages and disadvantages of vaccinations9a are listed in also not life threatening.9b Table 1. In 1955, Jonas Salk initiated an inactivated polio vaccine Antigen. The component matching the structural array of (IPV), aer that, Albert Sabin further developed the live, OPV. disease-oriented organisms, wherein, they are identied by the Even though poliovirus has three serotypes, both vaccines are immune system as ‘foreign’ and cause an active immune trivalent and offer good resistivity against poliomyelitis, response. a limited number of countries have continuously provided IPV. Stabilizer. This module is employed to assist the vaccine by Sabin’s OPV vaccine is underused in most countries due to sustaining its efficiency during storage. Instability of the minimising oral management, but it advances immunity in the This article is licensed under a vaccine can lead to reduced antigenicity and decreased infec- intestine, which is capable of spreading to others, and is asso- tivity of live attenuated vaccine (LAV). Magnesium chloride ciated with lower cost.9c (MgCl2) for oral polio vaccine (OPV), magnesium sulfate Preservatives. They are added in multi-dose vaccines, which Open Access Article. Published on 08 June 2021. Downloaded 9/28/2021 7:21:02 PM. (MgSO4) in measles vaccines, and lactose and gelatin associated can be used to control bacterial and fungal growth, including with sorbitol, are current representatives of stabilizing factors. thiomersal (sodium(2-carboxylatophenyl)sulfanyl-ethyl Adjuvant. They are responsible for enhancing the efficacy of mercury), formaldehyde, or phenolic derivatives. In fact, form- the vaccine by motivating the generation of antibodies. aldehyde is responsible for inactivating the viruses (e.g. IPV) and removing toxicity in bacterial strains, including the toxin employed in diphtheria and tetanus vaccines. Doble is a professor (Emeritus) in the Department of Biotechnology at the Indian Institute of Tech- Types of vaccines nology Madras (IITM). He Various kinds of vaccines are available and those which are worked for 23 years at Imperial administered to infants and adults can be classied (Fig. 1) as Chemical Industries and General follows: Electric Technology centers. His Live-attenuated. areas of interest are biomate- Inactivated. rials, drug design, bioreactors Toxoid. and bioremediation. He holds B. Conjugate. Tech and M. Tech degrees in Subunit. chemical engineering (IITM), and Live attenuated vaccines. These vaccines are adapted from a PhD (University of Aston, Bir- the existing bacteria or virus, they have been weakened, and mingham, UK) and has postdoctoral experience (University of thus will not result in serious disease in people with strong Cambridge, UK, and Texas A & M, USA). He has authored 320 immunity. LAV vaccines are more similar to the actual infec- technical papers, 10 books, and led 15 patents
Load more

Recommended publications
  • Mercury and Vaccinations
    MERCURYMERCURY ANDAND VACCINESVACCINES FACT SHEET, OCTOBER 2006 What is the concern about mercury in vaccines? Thimerosal, also known as thiomersal, is a preservative used in a number of biological and pharmaceutical products, including some flu and many multi-dose vaccines used for child immunisation. Mercury makes up approximately 50% of the weight of thimerosal in the organic form of ethylmercury. Thimerosal has been added to products to help prevent the growth of microbes since the 1930s. As more has become known about the effects of mercury on human health, the use of thimerosal in vaccines became an issue of increasing concern. Over the years, with more and more childhood vaccinations recommended or required, the amount of mercury to which infants and young children are being exposed has signifi- cantly increased. While there were no toxic effects reported in the first study of thimerosal use in humans, published in 1931, the study was not specifically designed to examine toxicity and was flawed in a number of other ways.1 Studies of any potential effects of thimerosal exposure in humans are ongoing and no general scientific consensus currently exists. Questions have particularly arisen around a possible connection between thimerosal and autism. Additionally, research is being conducted into the relationship between mercury exposure and Alzheimer’s disease. In 2004, a statement from the European Agency for the Evaluation of Medicinal Products (EMEA) noted that new toxicity studies demonstrate that ethylmercury is less toxic than methylmercury, the form people ingest by eating some types of fish.2 The following year, the report of the Immunisation Safety Review Committee produced by the US Institute of Medicine found again that reviewed evidence “favours a rejection of a causal relationship between thimerosal-containing vaccines and autism.”3 Yet, others have suggested that new toxicological data shows that there could be a plausible connection between thi- merosal and neurological effects in animals and humans.
    [Show full text]
  • Gamma-Irradiated SARS-Cov-2 Vaccine Candidate, OZG-38.61.3, Confers Protection from SARS-Cov-2 Challenge in Human ACEII-Transgen
    www.nature.com/scientificreports OPEN Gamma‑irradiated SARS‑CoV‑2 vaccine candidate, OZG‑38.61.3, confers protection from SARS‑CoV‑2 challenge in human ACEII‑transgenic mice Raife Dilek Turan1,2,19, Cihan Tastan1,3,4,19*, Derya Dilek Kancagi1,19, Bulut Yurtsever1,19, Gozde Sir Karakus1,19, Samed Ozer5, Selen Abanuz1,6, Didem Cakirsoy1,8, Gamze Tumentemur7, Sevda Demir2, Utku Seyis1, Recai Kuzay1, Muhammer Elek1,2, Miyase Ezgi Kocaoglu1, Gurcan Ertop7, Serap Arbak9, Merve Acikel Elmas9, Cansu Hemsinlioglu1, Ozden Hatirnaz Ng10, Sezer Akyoney10,11, Ilayda Sahin8,12, Cavit Kerem Kayhan13, Fatma Tokat14, Gurler Akpinar15, Murat Kasap15, Ayse Sesin Kocagoz16, Ugur Ozbek12, Dilek Telci2, Fikrettin Sahin2, Koray Yalcin1,17, Siret Ratip18, Umit Ince14 & Ercument Ovali1 The SARS‑CoV‑2 virus caused the most severe pandemic around the world, and vaccine development for urgent use became a crucial issue. Inactivated virus formulated vaccines such as Hepatitis A and smallpox proved to be reliable approaches for immunization for prolonged periods. In this study, a gamma‑irradiated inactivated virus vaccine does not require an extra purifcation process, unlike the chemically inactivated vaccines. Hence, the novelty of our vaccine candidate (OZG‑38.61.3) is that it is a non‑adjuvant added, gamma‑irradiated, and intradermally applied inactive viral vaccine. Efciency and safety dose (either 1013 or 1014 viral RNA copy per dose) of OZG‑38.61.3 was initially determined in BALB/c mice. This was followed by testing the immunogenicity and protective efcacy of the vaccine. Human ACE2‑encoding transgenic mice were immunized and then infected with the SARS‑CoV‑2 virus for the challenge test.
    [Show full text]
  • (ACIP) General Best Guidance for Immunization
    8. Altered Immunocompetence Updates This section incorporates general content from the Infectious Diseases Society of America policy statement, 2013 IDSA Clinical Practice Guideline for Vaccination of the Immunocompromised Host (1), to which CDC provided input in November 2011. The evidence supporting this guidance is based on expert opinion and arrived at by consensus. General Principles Altered immunocompetence, a term often used synonymously with immunosuppression, immunodeficiency, and immunocompromise, can be classified as primary or secondary. Primary immunodeficiencies generally are inherited and include conditions defined by an inherent absence or quantitative deficiency of cellular, humoral, or both components that provide immunity. Examples include congenital immunodeficiency diseases such as X- linked agammaglobulinemia, SCID, and chronic granulomatous disease. Secondary immunodeficiency is acquired and is defined by loss or qualitative deficiency in cellular or humoral immune components that occurs as a result of a disease process or its therapy. Examples of secondary immunodeficiency include HIV infection, hematopoietic malignancies, treatment with radiation, and treatment with immunosuppressive drugs. The degree to which immunosuppressive drugs cause clinically significant immunodeficiency generally is dose related and varies by drug. Primary and secondary immunodeficiencies might include a combination of deficits in both cellular and humoral immunity. Certain conditions like asplenia and chronic renal disease also can cause altered immunocompetence. Determination of altered immunocompetence is important to the vaccine provider because incidence or severity of some vaccine-preventable diseases is higher in persons with altered immunocompetence; therefore, certain vaccines (e.g., inactivated influenza vaccine, pneumococcal vaccines) are recommended specifically for persons with these diseases (2,3). Administration of live vaccines might need to be deferred until immune function has improved.
    [Show full text]
  • Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP)
    Morbidity and Mortality Weekly Report Recommendations and Reports February 8, 2002 / Vol. 51 / No. RR-2 General Recommendations on Immunization Recommendations of the Advisory Committee on Immunization Practices (ACIP) and the American Academy of Family Physicians (AAFP) INSIDE: Continuing Education Examination Centers for Disease Control and Prevention SAFER • HEALTHIER • PEOPLETM MMWR CONTENTS The MMWR series of publications is published by the Introduction ......................................................................... 1 Epidemiology Program Office, Centers for Disease Timing and Spacing of Immunobiologics .............................. 2 General Principles for Vaccine Scheduling ......................... 2 Control and Prevention (CDC), U.S. Department of Spacing of Multiple Doses of the Same Antigen ................ 2 Health and Human Services, Atlanta, GA 30333. Simultaneous Administration ............................................ 4 Nonsimultaneous Administration ...................................... 5 Spacing of Antibody-Containing Products and Vaccines ..... 6 SUGGESTED CITATION Interchangeability of Vaccines from Different Manufacturers 8 Centers for Disease Control and Prevention. General Lapsed Vaccination Schedule ............................................ 8 recommendations on immunization: recom- Unknown or Uncertain Vaccination Status ......................... 8 mendations of the Advisory Committee on Contraindications and Precautions ....................................... 8 Immunization Practices and the
    [Show full text]
  • NHSGGC COVID Vaccine Faqs for Health and Social Care Staff Version 06 12/01/21
    NHSGGC COVID Vaccine FAQs for Health and Social Care Staff Version 06 12/01/21 Link to Green Book Chapter on COVID Vaccine MHRA vaccine approval JCVI recommendations CMO Letter COVID Vaccination Programme These FAQs relate to the Pzifer/BioNTech and AstraZeneca vaccine COVID-19 vaccine The FAQs will be frequently updated as new information becomes available Any printed version will quickly be outdated, always check the NHSGGC webpage for the most up-to-date advice Sections in this document 1. Vaccine Details 2. Current illness and COVID vaccine 3. Flu Vaccine 4. I am immunosuppressed 5. I have previously had a positive COVID test result 6. I have taken part in a COVID vaccine trial 7. Infection Control 8. Nursing Homes 9. Pregnancy and Breastfeeding 10. Allergies and anaphylaxis and other medications 11. Staff Queries – General 12. COVID Vaccines and other vaccines 13. How to become a vaccinator 14. Appointments NHSGGC COVID Vaccine FAQs for Health and Social Care Staff Version 06 12/01/21 Section 1: Vaccine Details Are they live vaccines? No. Neither the Pfizer-BioNTech vaccine nor the AstraZeneca (AZ) vaccine are live vaccines. The AZ vaccine uses an adenovirus, but as it cannot replicate it is not a live vaccine. How is the COVID-19 vaccine given? You will be given an injection in your upper arm. You will need two doses, the second will be offered 12 weeks after the first dose. During your vaccination, strict infection prevention and control measures will be in place. Will a vaccine booster be required? The schedule requires two doses.
    [Show full text]
  • COVID-19 Vaccination Strategy in China: a Case Study
    Article COVID-19 Vaccination Strategy in China: A Case Study Marjan Mohamadi 1,†, Yuling Lin 1,*,† ,Mélissa Vuillet Soit Vulliet 1,†, Antoine Flahault 1, Liudmila Rozanova 1 and Guilhem Fabre 2 1 Institute of Global Health, University of Geneva, 1211 Geneva, Switzerland; [email protected] (M.M.); [email protected] (M.V.S.V.); antoine.fl[email protected] (A.F.); [email protected] (L.R.) 2 Department of Chinese, UFR 2, Université Paul Valéry Montpellier 3, 34199 Montpellier, France; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work. Abstract: The coronavirus disease 2019 (COVID-19) outbreak in China was first reported to the World Health Organization on 31 December 2019, after the first cases were officially identified around 8 December 2019. However, the case of an infected patient of 55 years old can probably be traced back on 17 November. The spreading has been rapid and heterogeneous. Economic, political and social impacts have not been long overdue. This paper, based on English, French and Chinese research in national and international databases, aims to study the COVID-19 situation in China through the management of the outbreak and the Chinese response to vaccination strategy. The coronavirus disease pandemic is under control in China through non-pharmaceutical interventions, and the mass vaccination program has been launched to further prevent the disease and progressed steadily with Citation: Mohamadi, M.; Lin, Y.; 483.34 million doses having been administered across the country by 21 May 2021. China is also Vulliet, M.V.S.; Flahault, A.; acting as an important player in the development and production of SARS-CoV-2 vaccines.
    [Show full text]
  • Opinions of Parents Concerning Childhood Vaccine Refusal and Factors Affecting Vaccination in Konya
    96 ORIGINAL ARTICLE DOI: 10.4274/gulhane.galenos.2020.1312 Gulhane Med J 2021;63:96-103 Opinions of parents concerning childhood vaccine refusal and factors affecting vaccination in Konya Hüseyin İlter1, Lütfi Saltuk Demir2 1Ministry of Health General Directorate of Public Health, Ankara, Turkey 2Necmettin Erbakan University Faculty Meram of Medicine, Department of Public Health, Konya, Turkey Date submitted: ABSTRACT 04.08.2020 Aims: The purpose of this study was to reveal the opinions, knowledge, and attitudes of parents Date accepted: in Konya, who refuse vaccination, concerning vaccine refusal. 05.10.2020 Online publication date: Methods: The study has a cross-sectional design. The research data were collected in 2019 15.06.2021 using a survey form developed by the researchers. The survey form was filled out by the parents of children in the 0-4 age group who had not been vaccinated in Konya and its districts in 2017. We were able to reach 801 out of 923 children who had not been vaccinated and still Corresponding Author: living in Konya. The parents of 590 children (73.7%) who agreed to participate in the study were Hüseyin İlter, M.D., Ministry of Health interviewed. General Directorate of Public Health, Results: The most commonly refused type of vaccination was hepatitis A, whereas the least Ankara, Turkey was hepatitis B. The most common reasons for vaccine refusal were believing that vaccines were not safe (63.9%), not believing that vaccines were useful and necessary (57.6%), and not ORCID: orcid.org/0000-0002-4452-8902 trusting vaccines because they were produced overseas (47.3%).
    [Show full text]
  • Immunisation How Vaccines Work
    Immunisation How vaccines work Dr Fiona Ryan Consultant in Public Health Medicine, Department of Public Health April 2015 Presentation Outline • An understanding of the following principles • Overview of immunity • Different types of vaccines and vaccine contents • Vaccine failures • Time intervals between vaccine doses • Vaccine overload • Adverse reactions • Herd immunity Immunity Immunity • – The ability of the human body to protect itself from infectious disease The immune system • Cells with a protective function in the – bone marrow –thymus – lymphatic system of ducts and nodes – spleen – blood Types of immunity Source: http://en.wikipedia.org/wiki/Immunological_memory Natural (innate) immunity Non-specific mechanisms – Physical barriers • skin and mucous membranes – Chemical barriers • gastric and digestive enzymes – Cellular and protein secretions • phagocytes, macrophages, complement system ** No “memory” of protection exists afterwards ** Passive immunity – adaptive mechanisms Natural • maternal transfer of antibodies to infant via placenta Artificial • administration of pre- formed substance to provide immediate but short-term protection (anti- toxin, antibodies) Protection is temporary and wanes with time (usually few months) Active immunity – adaptive mechanisms Natural • following contact with organism Artificial • administration of agent to stimulate immune response (immunisation) Acquired through contact with an micro-organism Protection produced by individual’s own immune system Protection often life-long but may need
    [Show full text]
  • Prospecting for an HIV Vaccine D
    Brett-Major et al. Tropical Diseases, Travel Medicine and Vaccines (2017) 3:6 DOI 10.1186/s40794-017-0050-4 REVIEW Open Access Prospecting for an HIV vaccine D. M. Brett-Major1,2*, T. A. Crowell1,2 and N. L. Michael1 Abstract Human immunodeficiency virus (HIV) sets several challenges for the development of a preventative HIV vaccine. Predictable, protective natural immunity against HIV does not occur and so unlike most other diseases for which vaccines exist, there are few guideposts from natural infection. Nonetheless, six vaccine efficacy trials have occurred. One in particular, the Thai trial called RV144, showed partial protective efficacy and potential ways ahead to a better vaccine approach. This coupled with other lessons from studies of acute infections as well as an increasingly complex knowledge of HIV-related vaccine immunology bring hope that a vaccine solution might be reached for this pervasive and deadly pandemic. Keywords: Human immunodeficiency virus vaccine protective efficacy immunology review Background Why not already Human immunodeficiency virus (HIV) disease remains A reasonable person new to the global conversation one of the greatest threats to global public health. about HIV might ask, if an HIV vaccine is so critical and According to the World Health Organization (WHO), in the pandemic known for three decades, why do we not 2014 over one million people died from HIV, nearly already have an HIV vaccine? There is no simple answer thirty-seven million people had chronic infection and to this question, though an easy one is that people do two million people newly acquired infections [1]. Of not develop natural, protective immunity to HIV infec- those persons known to be HIV infected, only 35% tion and disease.
    [Show full text]
  • The Model of “Informed Refusal” for Vaccination: How to Fight Against Anti-Vaccinationist Misinformation Without Disregarding the Principle of Self-Determination
    Communication The Model of “Informed Refusal” for Vaccination: How to Fight against Anti-Vaccinationist Misinformation without Disregarding the Principle of Self-Determination Stefano D’Errico 1, Emanuela Turillazzi 2, Martina Zanon 1, Rocco Valerio Viola 3, Paola Frati 3,4 and Vittorio Fineschi 3,4,* 1 Department of Surgery, Medicine and Health, University of Trieste, 34149 Trieste, Italy; [email protected] (S.D.); [email protected] (M.Z.) 2 Department of Surgical Pathology, Medical, Molecular and Critical Area, Institute of Legal Medicine, University of Pisa, 56126 Pisa, Italy; [email protected] 3 Department of Anatomical, Histological, Forensic and Orthopaedic Sciences, Sapienza University of Rome, Viale Regina Elena 336, 00161 Rome, Italy; [email protected] (R.V.V.); [email protected] (P.F.) 4 IRCCS (Istituto di Ricerca e Cura a Carattere Scientifico) Neuromed Mediterranean Neurological Institute, Via Atinense 18, 86077 Pozzilli, Italy * Correspondence: [email protected]; Tel.: +39 06 49912722 Abstract: Vaccines are arguably a public health success story as well as an incredibly cost-effective medical resource. Despite this, worldwide concerns about their safety are growing, with the risk of Citation: D’Errico, S.; Turillazzi, E.; increased morbidity and mortality in vaccine-preventable diseases because of vaccine refusal. The Zanon, M.; Viola, R.V.; Frati, P.; global political trend in developed countries is to increasingly reduce mandates and the compulsory Fineschi, V. The Model of “Informed nature of vaccination programs. This is due to strong opposition from anti-vaccination movements Refusal” For Vaccination: How to and groups. While these have existed since the beginnings of vaccinology, they have recently gained Fight Against Anti-Vaccinationist a strong foothold through massive exploitation of the media and especially the internet.
    [Show full text]
  • Meningococcal a Conjugate Vaccine Into the Routine Immunization Programme
    GUIDE TO INTRODUCING MENINGOCOCCAL A CONJUGATE VACCINE INTO THE ROUTINE IMMUNIZATION PROGRAMME GUIDE TO INTRODUCING MENINGOCOCCAL A CONJUGATE VACCINE INTO THE ROUTINE IMMUNIZATION PROGRAMME This publication was jointly developed by the WHO Regional Office for Africa and WHO headquarters. Guide to introducing meningococcal A conjugate vaccine into the routine immunization programme ISBN 978-92-4-151686-0 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial- ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc- sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. Guide to introducing meningococcal A conjugate vaccine into the routine immunization programme.
    [Show full text]
  • Expres2ion Biotech Holding Sponsored Research Initiating Coverage 24 June 2021
    ExpreS2ion Biotech Holding Sponsored Research Initiating Coverage 24 June 2021 Rising to the COVID-19 challenge ExpreS2ion Biotech is a contract research organization, which has been founded over 10 years ago. The company specializes in the production of complex proteins using its proprietary protein Target price (SEK) 60 expression platform. More recently, the company has been focusing Share price (SEK) 36 on the development of its pipeline, which includes several vaccine and therapeutic candidates. Out of this group, we regard the Forecast changes ABNCoV2 project (COVID-19 vaccine), carrying the highest near- % 2021e 2022e 2023e term potential. Its partner, Bavarian Nordic, plans to start Phase III Revenues NM NM NM trial later this year, pending funding. We expect an upward EBITDA NM NM NM EBIT adj NM NM NM potential rerating of SEK 50 per share, should the vaccine EPS reported NM NM NM successfully go through clinical development and receive regulatory EPS adj NM NM NM approval. We initiate coverage of ExpreS2ion Biotech with a Buy Source: Pareto rating, target price SEK 60 per share. Ticker EXPRS2.ST, EXPRS2 SS Sector Healthcare COVID-19 vaccine project carries the highest near-term potential Shares fully diluted (m) 27.6 Market cap (SEKm) 988 Despite the rapid success of a number of COVID-19 vaccines, there is Net debt (SEKm) -114 a need for improved vaccines that offer strong immunogenicity as Minority interests (SEKm) 0 well as ease of clinical administration, stability and adaptiveness of Enterprise value 21e (SEKm) 938 platform. Given impressive pre-clinical results, as well as solid interim Free float (%) 83 Phase I safety data, we believe ABNCoV2 has a significant opportunity to succeed through the rest of clinical development.
    [Show full text]